Publicaciones en las que colabora con Javier Zulueta Frances (33)

2024

  1. Lung Cancer Screening in People With COPD: The Pamplona-IELCAP Experience

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 95-100

  2. Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery

    Journal of Thoracic Oncology, Vol. 19, Núm. 3, pp. 476-490

  3. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2023

  1. Circulating proteome for pulmonary nodule malignancy

    Journal of the National Cancer Institute, Vol. 115, Núm. 9, pp. 1060-1070

  2. Lung cancer screening using low-dose CT and FDG-PET in liver transplant recipients

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, Vol. 29, Núm. 10, pp. 1100-1108

2021

  1. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

    Translational Research, Vol. 233, pp. 77-91

  2. Molecular biomarkers in early stage lung cancer

    Translational Lung Cancer Research, Vol. 10, Núm. 2, pp. 1165-1185

2020

  1. Avances en el manejo del cáncer de pulmón

    Anales del sistema sanitario de Navarra, Vol. 43, Núm. 2, pp. 131-139

2019

  1. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

    Journal of Thoracic Oncology, Vol. 14, Núm. 3, pp. 343-357

  2. CT screening for lung cancer: comparison of three baseline screening protocols

    European Radiology, Vol. 29, Núm. 10, pp. 5217-5226

2017

  1. Telomere length, COPD and emphysema as risk factors for lung cancer

    European Respiratory Journal

2016

  1. A novel epigenetic signature for early diagnosis in lung cancer

    Clinical Cancer Research, Vol. 22, Núm. 13, pp. 3361-3371

2015

  1. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer

    PLoS ONE, Vol. 10, Núm. 3

  2. Improving selection criteria for lung cancer screening: The potential role of emphysema

    American Journal of Respiratory and Critical Care Medicine, Vol. 191, Núm. 8, pp. 924-931

2013

  1. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer

    Journal of the National Cancer Institute, Vol. 105, Núm. 18, pp. 1385-1393

  2. Smokers with CT Detected Emphysema and No Airway Obstruction Have Decreased Plasma Levels of EGF, IL-15, IL-8 and IL-1ra

    PLoS ONE, Vol. 8, Núm. 4

2012

  1. Re: Inconsistencies in findings from the early lung cancer action project studies of lung cancer screening

    Journal of the National Cancer Institute

2011

  1. Evaluation of micro-CT for emphysema assessment in mice: Comparison with non-radiological techniques

    European Radiology, Vol. 21, Núm. 5, pp. 954-962

  2. Robust, Standardized Quantification of Pulmonary Emphysema in Low Dose CT Exams

    Academic Radiology, Vol. 18, Núm. 11, pp. 1382-1390

2010

  1. Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer

    Cancer Epidemiology Biomarkers and Prevention, Vol. 19, Núm. 10, pp. 2665-2672